Fernando Mejia, MD
Psychiatry · Miami, FLNPI 1225143472
Payments from drug & device makers
Across 71 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$225
- Neurocrine Biosciences, Inc.$186
- AbbVie$179
- Teva Pharmaceuticals USA, Inc.$134
- Shire North American Group Inc$74
- Takeda Pharmaceuticals U.S.A., Inc.$71
- plus $165 from 5 others
What the payments were for
- Food & beverage$1,030100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 14 | $225 |
| Neurocrine Biosciences, Inc. | 9 | $186 |
| AbbVie | 14 | $179 |
| Teva Pharmaceuticals USA, Inc. | 17 | $134 |
| Shire North American Group Inc | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Johnson & Johnson | 3 | $43 |
| Abiomed | 2 | $31 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
How this compares
$1,033 in reported general payments places this provider in the 60th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 43 | $558 |
| Quetiapine Fumarate | 32 | $497 |
| Trazodone Hcl | 100 | $496 |
| Clonazepam | 41 | $414 |
| Aripiprazole | 12 | $391 |
| Escitalopram Oxalate | 43 | $300 |
| Bupropion Hcl SrBupropion Hcl | 19 | $251 |
| Duloxetine Hcl | 36 | $240 |
| Temazepam | 33 | $239 |
| Risperidone | 26 | $205 |
| Lamotrigine | 21 | $189 |
| Paroxetine Hcl | 15 | $106 |
| Gabapentin | 21 | $106 |
| Alprazolam | 26 | $102 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $98 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Miami
- Silvia Silva-DulucMiami$11.7M
- Patricia JunqueraMiami$10.8M
- Evelio SosaMiami$6.9M
- Mario CuervoMiami$6.7M
- Emelina ArochaMiami$4.9M
- Maria RodilMiami$4.5M
- Marc AgroninMiami$4M
- Nancy Navarro-GonzalezMiami$2.6M
- Francisco RicartMiami$2.6M
- Durim BozhdarajMiami$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.